The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic highlighted the most pressing needs within the Alzheimer disease community.
We went through a low of trudging along, and now we’re back to that new level of excitement. This is a very important watershed moment in our field.
As the Alzheimer disease (AD) community awaits the FDA decision of aducanumab, the shift focuses back to the research, and continuing to increase the momentum the AD community has gained over the past decade. The hope is that If approved, aducanumab may create the domino effect for other treatments and expand the current landscape further.
For now, there still remain multiple unmet needs for patients withAD despite the growing knowledge of the disease. Marwan Sabbagh, MD, director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic claimed that prevention of AD is the “sexy” option but is further away than people understand. He feels as though treatment options are more attainable and can ultimately make a greater impact now than focusing on prevention.
In an interview with NeurologyLive, Sabbagh makes his case for both prevention and treatment as the most pressing topics for the AD community. He also provides an outlook on future research and why other clinician communities should be buzzing more about aducanumab’s upcoming FDA decision.